Katelyn Byrne, Ph.D.

  • Assistant Professor of Cell, Developmental and Cancer Biology, School of Medicine
  • Member, Brenden-Colson Center for Pancreatic Care, OHSU Knight Cancer Institute, School of Medicine
  • Member, OHSU Knight Cancer Institute, School of Medicine

Biography

The Byrne Lab aims to understand the underlying immunobiology regulating therapeutic sensitivity in pancreatic cancer. Our research focuses on interrogating mechanisms of bridging innate and adaptive immunity that drive tumor rejection in preclinical models of cancer, and revealing correlates of response for patients receiving immunotherapy.

Education and training

  • Degrees

    • B.A., 2007, Boston University
    • Ph.D., 2013, Dartmouth College

  • Fellowship

    • American Cancer Society Post-doctoral Fellowship
    • Senior Parker Fellow, Parker Institute for Cancer Immunotherapy

Memberships and associations:

  • American Association for Cancer Research (AACR)
  • American Association of Immunologists (AAI)

Areas of interest

  • pancreatic cancer
  • immunotherapy
  • tumor microenvironment

Publications

Selected publications

  • Padrón LJ, Maurer DM, O’Hara MH, et al. Sotigalimab and/or nivolumab with chemotherapy in first-line metastatic pancreatic cancer: clinical and immunologic analyses from the randomized phase 2 PRINCE trial. Nat Med. 2022;28(6):1167-1177. doi:10.1038/s41591-022-01829-9
  • Byrne KT*, Betts CB*, Mick R*, et al. Neoadjuvant Selicrelumab, an Agonist CD40 Antibody, Induces Changes in the Tumor Microenvironment in Patients with Resectable Pancreatic Cancer. Clin Cancer Res. 2021;27(16):4574-4586. doi:10.1158/1078-0432.ccr-21-1047
  • Yang F, He Z, Duan H, et al. Synergistic immunotherapy of glioblastoma by dual targeting of IL-6 and CD40. Nat Commun. 2021;12(1):3424. doi:10.1038/s41467-021-23832-3
  • Roehle K, Qiang L, Ventre KS, et al. cIAP1/2 antagonism eliminates MHC class I–negative tumors through T cell–dependent reprogramming of mononuclear phagocytes. Sci Transl Med. 2021;13(594):eabf5058. doi:10.1126/scitranslmed.abf5058
  • Kim SI, Cassella CR, Byrne KT. Tumor Burden and Immunotherapy: Impact on Immune Infiltration and Therapeutic Outcomes. Front Immunol. 2021;11:629722. doi:10.3389/fimmu.2020.629722
  • O’Hara MH, O’Reilly EM, Varadhachary G, et al. CD40 agonistic monoclonal antibody APX005M (sotigalimab) and chemotherapy, with or without nivolumab, for the treatment of metastatic pancreatic adenocarcinoma: an open-label, multicentre, phase 1b study. Lancet Oncol. 2021;22(1):118-131. doi:10.1016/s1470-2045(20)30532-5
  • Huffman AP, Lin JH, Kim SI, Byrne KT, Vonderheide RH. CCL5 mediates CD40-driven CD4+ T-cell tumor infiltration and immunity. JCI Insight. Published online 2020. doi:10.1172/jci.insight.137263
  • Morrison AH, Diamond MS, Hay CA, Byrne KT*, Vonderheide RH*. Sufficiency of CD40 activation and immune checkpoint blockade for T cell priming and tumor immunity. Proc National Acad Sci. Published online 2020:201918971. doi:10.1073/pnas.1918971117
  • Hay CA, Sor R, Flowers AJ, Clendenin C, Byrne KT. Ultrasound-Guided Orthotopic Implantation of Murine Pancreatic Ductal Adenocarcinoma. J Vis Exp. 2019;(153). doi:10.3791/60497
  • Markosyan N, Li J, Sun YH, et al. Tumor cell-intrinsic EPHA2 suppresses anti-tumor immunity by regulating PTGS2 (COX-2). J Clin Invest. 2019;129(9):3594-3609. doi:10.1172/jci127755
  • Li J*, Byrne KT*, Yan F, et al. Tumor Cell-Intrinsic Factors Underlie Heterogeneity of Immune Cell Infiltration and Response to Immunotherapy. Immunity. 2018;49(1):178-193.e7. doi:10.1016/j.immuni.2018.06.006

Publications